vs

Side-by-side financial comparison of Direct Digital Holdings, Inc. (DRCT) and Fortress Biotech, Inc. (FBIO). Click either name above to swap in a different company.

Fortress Biotech, Inc. is the larger business by last-quarter revenue ($16.1M vs $8.4M, roughly 1.9× Direct Digital Holdings, Inc.). Fortress Biotech, Inc. runs the higher net margin — -24.5% vs -138.7%, a 114.2% gap on every dollar of revenue. On growth, Fortress Biotech, Inc. posted the faster year-over-year revenue change (6.3% vs -7.4%). Over the past eight quarters, Fortress Biotech, Inc.'s revenue compounded faster (11.0% CAGR vs -38.6%).

Devolver Digital, Inc. is an American video game publisher based in Austin, Texas, specializing in the publishing of indie games. The company was founded in June 2009 by Nigel Lowrie, Harry Miller, Graeme Struthers, Rick Stults, and Mike Wilson, five executives who had been involved with Gathering of Developers and Gamecock Media Group, which published games on developer-friendly terms, but due to the high cost associated with releasing retail games saw themselves acquired and dissolved by la...

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

DRCT vs FBIO — Head-to-Head

Bigger by revenue
FBIO
FBIO
1.9× larger
FBIO
$16.1M
$8.4M
DRCT
Growing faster (revenue YoY)
FBIO
FBIO
+13.7% gap
FBIO
6.3%
-7.4%
DRCT
Higher net margin
FBIO
FBIO
114.2% more per $
FBIO
-24.5%
-138.7%
DRCT
Faster 2-yr revenue CAGR
FBIO
FBIO
Annualised
FBIO
11.0%
-38.6%
DRCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DRCT
DRCT
FBIO
FBIO
Revenue
$8.4M
$16.1M
Net Profit
$-11.7M
$-3.9M
Gross Margin
26.8%
66.1%
Operating Margin
-53.4%
-28.8%
Net Margin
-138.7%
-24.5%
Revenue YoY
-7.4%
6.3%
Net Profit YoY
-434.7%
41.8%
EPS (diluted)
$-74.97
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DRCT
DRCT
FBIO
FBIO
Q4 25
$8.4M
$16.1M
Q3 25
$8.0M
$17.6M
Q2 25
$10.1M
$16.4M
Q1 25
$8.2M
$13.1M
Q4 24
$9.1M
$15.1M
Q3 24
$9.1M
$14.6M
Q2 24
$21.9M
$14.9M
Q1 24
$22.3M
$13.0M
Net Profit
DRCT
DRCT
FBIO
FBIO
Q4 25
$-11.7M
$-3.9M
Q3 25
$-2.7M
$5.8M
Q2 25
$-2.2M
$15.5M
Q1 25
$-2.4M
$-10.6M
Q4 24
$-2.2M
$-6.8M
Q3 24
$-2.7M
$-12.9M
Q2 24
$-590.0K
$-10.9M
Q1 24
$-775.0K
$-15.4M
Gross Margin
DRCT
DRCT
FBIO
FBIO
Q4 25
26.8%
66.1%
Q3 25
27.7%
67.4%
Q2 25
35.1%
69.9%
Q1 25
29.3%
63.5%
Q4 24
32.5%
69.1%
Q3 24
38.7%
69.4%
Q2 24
27.1%
61.6%
Q1 24
22.4%
53.9%
Operating Margin
DRCT
DRCT
FBIO
FBIO
Q4 25
-53.4%
-28.8%
Q3 25
-49.0%
-38.6%
Q2 25
-23.9%
-222.2%
Q1 25
-48.1%
-169.9%
Q4 24
-51.8%
-158.3%
Q3 24
-40.3%
-151.0%
Q2 24
-9.4%
-186.5%
Q1 24
-12.6%
-280.6%
Net Margin
DRCT
DRCT
FBIO
FBIO
Q4 25
-138.7%
-24.5%
Q3 25
-33.6%
33.2%
Q2 25
-22.2%
94.4%
Q1 25
-28.9%
-80.6%
Q4 24
-24.0%
-44.7%
Q3 24
-29.6%
-88.0%
Q2 24
-2.7%
-73.5%
Q1 24
-3.5%
-118.3%
EPS (diluted)
DRCT
DRCT
FBIO
FBIO
Q4 25
$-74.97
$-0.15
Q3 25
$-0.24
$0.11
Q2 25
$-0.23
$0.45
Q1 25
$-0.35
$-0.48
Q4 24
$-90.17
$-0.16
Q3 24
$-0.71
$-0.76
Q2 24
$-0.16
$-0.73
Q1 24
$-0.22
$-1.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DRCT
DRCT
FBIO
FBIO
Cash + ST InvestmentsLiquidity on hand
$728.0K
$79.4M
Total DebtLower is stronger
$52.4M
Stockholders' EquityBook value
$-7.0M
$49.9M
Total Assets
$20.2M
$185.5M
Debt / EquityLower = less leverage
1.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DRCT
DRCT
FBIO
FBIO
Q4 25
$728.0K
$79.4M
Q3 25
$871.0K
$86.2M
Q2 25
$1.6M
$74.4M
Q1 25
$1.8M
$91.3M
Q4 24
$1.4M
$57.3M
Q3 24
$4.1M
$58.9M
Q2 24
$1.1M
$76.2M
Q1 24
$3.3M
$83.8M
Total Debt
DRCT
DRCT
FBIO
FBIO
Q4 25
$52.4M
Q3 25
$10.8M
$47.8M
Q2 25
$33.5M
$50.0M
Q1 25
$32.9M
$56.4M
Q4 24
$58.0M
Q3 24
$150.0K
$52.5M
Q2 24
$34.8M
$67.0M
Q1 24
$32.4M
$61.4M
Stockholders' Equity
DRCT
DRCT
FBIO
FBIO
Q4 25
$-7.0M
$49.9M
Q3 25
$-6.7M
$55.9M
Q2 25
$-24.6M
$43.9M
Q1 25
$-23.3M
$22.3M
Q4 24
$-19.7M
$22.7M
Q3 24
$-16.7M
$21.2M
Q2 24
$-10.5M
$17.9M
Q1 24
$-7.5M
$23.0M
Total Assets
DRCT
DRCT
FBIO
FBIO
Q4 25
$20.2M
$185.5M
Q3 25
$22.5M
$181.4M
Q2 25
$23.3M
$159.9M
Q1 25
$23.8M
$178.1M
Q4 24
$26.0M
$144.2M
Q3 24
$31.3M
$127.1M
Q2 24
$48.5M
$145.7M
Q1 24
$52.8M
$164.6M
Debt / Equity
DRCT
DRCT
FBIO
FBIO
Q4 25
1.05×
Q3 25
0.86×
Q2 25
1.14×
Q1 25
2.53×
Q4 24
2.55×
Q3 24
2.48×
Q2 24
3.75×
Q1 24
2.67×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DRCT
DRCT
FBIO
FBIO
Operating Cash FlowLast quarter
$-1.9M
$-12.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DRCT
DRCT
FBIO
FBIO
Q4 25
$-1.9M
$-12.5M
Q3 25
$-1.6M
$-6.1M
Q2 25
$-2.7M
$-27.6M
Q1 25
$-2.7M
$-19.6M
Q4 24
$-1.6M
$-12.9M
Q3 24
$3.0M
$-20.1M
Q2 24
$-4.4M
$-21.8M
Q1 24
$-5.7M
$-25.4M
Capex Intensity
DRCT
DRCT
FBIO
FBIO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.0%
Q2 24
Q1 24
Cash Conversion
DRCT
DRCT
FBIO
FBIO
Q4 25
Q3 25
-1.04×
Q2 25
-1.78×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DRCT
DRCT

Buy Side Advertising$8.2M98%
Other$183.0K2%

FBIO
FBIO

Segment breakdown not available.

Related Comparisons